GSK Q3 Core Operating Profit Rises 5%, Reaffirms 2026 Guidance

GSK reported third-quarter core operating profit of 1.935 billion pounds, up 5% year-over-year at constant exchange rates, and reaffirmed its full-year 2026 guidance. Profit before tax fell to 1.935 billion pounds from 2.456 billion pounds a year earlier, while earnings per share declined to 38.5 pence from 49.9 pence. Core earnings per share rose 1% at CER to 54.6 pence. Total quarterly sales were 8.9 billion pounds, up 4% on an actual exchange rate basis, or 5% at CER. The company said turnover for 2026 is expected to increase 3% to 5%, core operating profit 7% to 9%, and core earnings per share 7% to 9%, all at constant exchange rates. GSK said it remains on track for its 2031 sales outlook of more than 40 billion pounds, and its dividend policy is unchanged. The board declared a third interim dividend of 17 pence per share, with the expected 2026 dividend at 70 pence per share. GSK shares closed at 1,916.20 pence on the LSE.